FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310937029> ?p ?o ?g. }

• W4310937029 endingPage "509" @default.
• W4310937029 startingPage "501" @default.
• W4310937029 abstract "Background Because of its antiarrhythmic potency and due to the lack of alternatives, amiodarone is often used for antiarrhythmic therapy in patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy–defibrillator systems. To date, robust data on the safety and clinical benefit of amiodarone therapy in these patients are missing. Objective The purpose of this study was to assess the periprocedural and postprocedural outcomes of combined therapy with beta-blockers plus amiodarone compared to treatment with single beta-blockers in the “real-life” cohort of ICD recipients of the German DEVICE registry. Methods A total of 4499 patients who underwent ICD implantation, revision, or upgrade in 49 centers participating in the German DEVICE registry were enrolled from March 2007 to February 2014. Results Amiodarone had no significant effect on the success of defibrillation testing. Early implantation-associated complications were similar between the groups. However, 1-year overall mortality was significantly higher in the beta-blocker plus amiodarone cohort (adjusted hazard ratio 2.09; P <.001). Interestingly, among the surviving patients, amiodarone was not associated with a significantly reduced risk of ICD discharges or syncopal events. Furthermore, the occurrence of ventricular tachycardia (VT) storm or incessant VTs and the number of patients scheduled for intracardiac ablation did not differ among both groups, whereas the rate of rehospitalization was lower in the cohort with only beta-blockers. Conclusions Although amiodarone has no adverse effect on the success of defibrillation testing, our data suggest an increased all-cause mortality under amiodarone therapy, especially in the subgroups of patients with sinus rhythm or severely reduced left ventricular function. In surviving patients, rates of arrhythmic events were comparable. Because of its antiarrhythmic potency and due to the lack of alternatives, amiodarone is often used for antiarrhythmic therapy in patients with implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy–defibrillator systems. To date, robust data on the safety and clinical benefit of amiodarone therapy in these patients are missing. The purpose of this study was to assess the periprocedural and postprocedural outcomes of combined therapy with beta-blockers plus amiodarone compared to treatment with single beta-blockers in the “real-life” cohort of ICD recipients of the German DEVICE registry. A total of 4499 patients who underwent ICD implantation, revision, or upgrade in 49 centers participating in the German DEVICE registry were enrolled from March 2007 to February 2014. Amiodarone had no significant effect on the success of defibrillation testing. Early implantation-associated complications were similar between the groups. However, 1-year overall mortality was significantly higher in the beta-blocker plus amiodarone cohort (adjusted hazard ratio 2.09; P <.001). Interestingly, among the surviving patients, amiodarone was not associated with a significantly reduced risk of ICD discharges or syncopal events. Furthermore, the occurrence of ventricular tachycardia (VT) storm or incessant VTs and the number of patients scheduled for intracardiac ablation did not differ among both groups, whereas the rate of rehospitalization was lower in the cohort with only beta-blockers. Although amiodarone has no adverse effect on the success of defibrillation testing, our data suggest an increased all-cause mortality under amiodarone therapy, especially in the subgroups of patients with sinus rhythm or severely reduced left ventricular function. In surviving patients, rates of arrhythmic events were comparable." @default.
• W4310937029 created "2022-12-21" @default.
• W4310937029 creator A5007851719 @default.
• W4310937029 creator A5008704300 @default.
• W4310937029 creator A5014743162 @default.
• W4310937029 creator A5019224180 @default.
• W4310937029 creator A5023382668 @default.
• W4310937029 creator A5024464721 @default.
• W4310937029 creator A5033538116 @default.
• W4310937029 creator A5037563041 @default.
• W4310937029 creator A5047948391 @default.
• W4310937029 creator A5056180665 @default.
• W4310937029 creator A5062919669 @default.
• W4310937029 creator A5068955846 @default.
• W4310937029 creator A5079753441 @default.
• W4310937029 creator A5086506266 @default.
• W4310937029 creator A5087524420 @default.
• W4310937029 date "2023-04-01" @default.
• W4310937029 modified "2023-10-17" @default.
• W4310937029 title "Single beta-blocker or combined amiodarone therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy—defibrillator patients: Insights from the German DEVICE registry" @default.
• W4310937029 cites W1965176844 @default.
• W4310937029 cites W2016958168 @default.
• W4310937029 cites W2024269966 @default.
• W4310937029 cites W2112829244 @default.
• W4310937029 cites W2119818163 @default.
• W4310937029 cites W2121221780 @default.
• W4310937029 cites W2135456762 @default.
• W4310937029 cites W2153052137 @default.
• W4310937029 cites W2161984704 @default.
• W4310937029 cites W2296998040 @default.
• W4310937029 cites W2332287011 @default.
• W4310937029 cites W2518105186 @default.
• W4310937029 cites W2599761051 @default.
• W4310937029 cites W2769632314 @default.
• W4310937029 cites W2900816551 @default.
• W4310937029 cites W3012210512 @default.
• W4310937029 cites W3105003765 @default.
• W4310937029 cites W3193598686 @default.
• W4310937029 cites W52877415 @default.
• W4310937029 doi "https://doi.org/10.1016/j.hrthm.2022.12.009" @default.
• W4310937029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36509321" @default.
• W4310937029 hasPublicationYear "2023" @default.
• W4310937029 type Work @default.
• W4310937029 citedByCount "4" @default.
• W4310937029 countsByYear W43109370292022 @default.
• W4310937029 countsByYear W43109370292023 @default.
• W4310937029 crossrefType "journal-article" @default.
• W4310937029 hasAuthorship W4310937029A5007851719 @default.
• W4310937029 hasAuthorship W4310937029A5008704300 @default.
• W4310937029 hasAuthorship W4310937029A5014743162 @default.
• W4310937029 hasAuthorship W4310937029A5019224180 @default.
• W4310937029 hasAuthorship W4310937029A5023382668 @default.
• W4310937029 hasAuthorship W4310937029A5024464721 @default.
• W4310937029 hasAuthorship W4310937029A5033538116 @default.
• W4310937029 hasAuthorship W4310937029A5037563041 @default.
• W4310937029 hasAuthorship W4310937029A5047948391 @default.
• W4310937029 hasAuthorship W4310937029A5056180665 @default.
• W4310937029 hasAuthorship W4310937029A5062919669 @default.
• W4310937029 hasAuthorship W4310937029A5068955846 @default.
• W4310937029 hasAuthorship W4310937029A5079753441 @default.
• W4310937029 hasAuthorship W4310937029A5086506266 @default.
• W4310937029 hasAuthorship W4310937029A5087524420 @default.
• W4310937029 hasConcept C126322002 @default.
• W4310937029 hasConcept C164705383 @default.
• W4310937029 hasConcept C197934379 @default.
• W4310937029 hasConcept C2776034619 @default.
• W4310937029 hasConcept C2776331378 @default.
• W4310937029 hasConcept C2777093960 @default.
• W4310937029 hasConcept C2777795826 @default.
• W4310937029 hasConcept C2778094803 @default.
• W4310937029 hasConcept C2778198053 @default.
• W4310937029 hasConcept C2779161974 @default.
• W4310937029 hasConcept C71924100 @default.
• W4310937029 hasConcept C72563966 @default.
• W4310937029 hasConcept C78085059 @default.
• W4310937029 hasConceptScore W4310937029C126322002 @default.
• W4310937029 hasConceptScore W4310937029C164705383 @default.
• W4310937029 hasConceptScore W4310937029C197934379 @default.
• W4310937029 hasConceptScore W4310937029C2776034619 @default.
• W4310937029 hasConceptScore W4310937029C2776331378 @default.
• W4310937029 hasConceptScore W4310937029C2777093960 @default.
• W4310937029 hasConceptScore W4310937029C2777795826 @default.
• W4310937029 hasConceptScore W4310937029C2778094803 @default.
• W4310937029 hasConceptScore W4310937029C2778198053 @default.
• W4310937029 hasConceptScore W4310937029C2779161974 @default.
• W4310937029 hasConceptScore W4310937029C71924100 @default.
• W4310937029 hasConceptScore W4310937029C72563966 @default.
• W4310937029 hasConceptScore W4310937029C78085059 @default.
• W4310937029 hasFunder F4320320879 @default.
• W4310937029 hasIssue "4" @default.
• W4310937029 hasLocation W43109370291 @default.
• W4310937029 hasLocation W43109370292 @default.
• W4310937029 hasOpenAccess W4310937029 @default.
• W4310937029 hasPrimaryLocation W43109370291 @default.
• W4310937029 hasRelatedWork W187959415 @default.
• W4310937029 hasRelatedWork W1994852664 @default.
• W4310937029 hasRelatedWork W2020548162 @default.
• W4310937029 hasRelatedWork W2029343151 @default.

• next